GlassScriptPhysician profile
Abha Kadam
NPI 1881062339
$2,215.13
in general payments reported to CMS, 2019-2025
22 companies · $1,036 in 2025
The $1,036 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.25 · 2022: $17.17 · 2023: $201 · 2024: $949 · 2025: $1,036.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,186.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $453.79 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $250.92 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $244.40 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $243.53 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $230.45 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $177.55 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Exact Sciences Corporation | $154.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Daiichi Sankyo INC. | $97.81 | 2024-2025 | Injectafer |
| Verona Pharma, INC. | $50.22 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $47.22 | 2025 | Inspire |
| Abbott Laboratories | $40.65 | 2025 | Freestyle Libre 3 |
| Collegium Pharmaceutical, INC. | $35.85 | 2024 | Xtampza, Belbuca |
| Pfizer INC. | $33.13 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $26.52 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Alkermes, INC. | $24.92 | 2024 | Vivitrol |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2024 | Eliquis |
| Sumitomo Pharma America, INC. | $15.95 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.83 | 2025 | Caplyta |
| Axsome Therapeutics, INC. | $14.93 | 2025 | Auvelity |
| Corium, LLC | $13.69 | 2023 | Azstarys |
| Amgen INC. | $13.30 | 2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.25 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abha Kadam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.